Posts by Mourabit Halima

On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To capture the conference's dynamics and facilitate in-depth exchange, Oncology Frontier - Hematology Frontier invited Dr. Kai Hu from Beijing GoBroad Hospital for an exclusive interview. He provided insightful explanations on the topic of "The Application of Immunotherapy in Lymphoma/Myeloma."

On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. At this conference, Dr. Lin Fu from the Department of Hematology at Beijing Tiantan Hospital delivered an insightful presentation on the "Advances in Diagnosis and Treatment of Primary Central Nervous System Lymphoma (PCNSL)." To capture the conference's dynamics and facilitate in-depth exchange, Oncology Frontier - Hematology Frontier conducted an exclusive interview with Dr. Lin Fu. The following is a summary for readers' reference.

Acute promyelocytic leukemia (APL) is a highly aggressive hematological disease, and its treatment has long been a challenge in the field. Chinese scholars have contributed significantly to global APL treatment with the introduction of the arsenic trioxide (ATO) regimen. Since the publication of the APL0406 study in NEJM in 2013, the combination of all-trans retinoic acid (ATRA) and ATO has replaced ATRA combined with chemotherapy as the standard treatment for low- and intermediate-risk APL patients. However, whether this regimen is suitable for high-risk APL patients remains undetermined due to a lack of randomized controlled trials. At the 29th Annual Meeting of the European Hematology Association (EHA 2024) held from June 13-16, 2024, Dr. Uwe Platzbecker from the Leipzig University in Germany presented key findings from the APOLLO study. This study demonstrated that the combination of ATO and ATRA offers a new treatment strategy for high-risk APL patients, providing valuable insights into the current state of APL treatment and guiding future research directions and clinical practices. Oncology Frontier - Hematology Frontier invited Professor Platzbecker to share the important discoveries and clinical significance of the APOLLO study.

On July 20, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was grandly held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To deepen the exchange and discussion, Oncology Frontier - Hematology Frontier invited Dr. Xiaoyan Ke from the Peking University Third Hospital/Beijing GoBroad Hospital for an exclusive interview to discuss advancements in the field and share academic insights.

On July 20, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To deepen the exchange and discussion, Oncology Frontier - Hematology Frontier invited Dr. Jihao Zhou from Shenzhen People's Hospital for an exclusive interview to discuss advancements in the field and share academic insights.

Dr. Andreas Greinacher, with over 35 years of extensive experience, has brought groundbreaking scientific discoveries to the field of hematology through his critical thinking and relentless curiosity. At the highly anticipated 2024 International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting, he was awarded the prestigious Robert P. Grant Medal, showcasing his profound expertise and significant contributions to the field of thrombosis and hemostasis.

The International Society on Thrombosis and Haemostasis (ISTH) is an inclusive organization with a global perspective, providing a valuable platform for scholars from around the world to engage, interact, and collaborate. Dr. David Lillicrap, a professor in the Department of Pathology and Molecular Medicine at Queen's University in Canada, was honored with the Harold R. Roberts Award at the ISTH 2024 meeting. This award recognizes individuals who have steadfastly supported the mission of the ISTH Scientific and Standardization Committee (SSC) through selfless dedication and expertise. As an outstanding hematologist and researcher, Dr. Lillicrap enjoys high acclaim in the field and has held several leadership positions within ISTH, including the Chair of the ISTH SSC. The Roberts Award not only acknowledges his exceptional service to the ISTH SSC but also celebrates his extraordinary dedication and lasting contributions.

The International Society on Thrombosis and Haemostasis (ISTH) announced the winners of the 2024 Fundamental Research Career Development Awards at the conference. This award aims to recognize early-career researchers who have made outstanding achievements in basic research. By acknowledging and encouraging these young scientists' innovative ideas, ISTH hopes to support them on their path to independent research, thereby strengthening the field of basic research. Each awardee will receive a grant to support their research, training, and collaborative studies in their respective fields. This award program, meticulously planned by the ISTH Fundamental Research Working Group under the guidance of the Education Committee, is designed as a career development incentive for promising early-career researchers.